Just one dose of psilocybin significantly improved depression symptoms and functional disability in patients with major depressive disorder (MDD), a randomized trial found....
Are faster drug approvals by the FDA hurting the public's overall perception of clinical research?...
Commenters on the FDA's guidance on clinical investigations and drug development programs for psychedelic drugs raised concerns about decoupling drug administration from psychotherapy support, the proposed credentials for lead safety monitors and the agency’s characterization of the abuse potential of psychedelic drugs....
UW–Madison has joined a statewide consortium, mobilizing its experience and expertise as a collaborative powerhouse in bioscience and technology to help bolster Wisconsin’s leadership in personalized medicine and biohealth technology....
Clinicians and consumers are deprived of the full picture needed for informed decision-making....
Arabs are are often categorized as white in clinical research. Grouping individuals from diverse genetic backgrounds under a single racial category can be problematic in clinical research....
They might not be popular, but a major report shows combining these interventions can keep case numbers low....
Since 1973, UW Carbone has remained at the forefront of life-saving discoveries as Wisconsin’s only National Cancer Institute (NCI)-designated comprehensive cancer center....
Working with scientists at the pharmaceutical maker Merck & Co. Inc., UW–Madison chemists and engineers sought to develop a more sustainable method to manufacture ingredients needed to make many types of drugs....
n a recent Clinical Leader Live! episode hosted by Life Science Leader Chief Editor Ben Comer, clinical trial experts Mitchell Katz, SVP, global clinical operations at Kyowa Kirin; Jessica Powell, VP, clinical operations at Alto Neuroscience; and Michael Krams, chief quantitative medicine officer at Exscientia,...
